Skip to main content
. Author manuscript; available in PMC: 2008 Apr 30.
Published in final edited form as: Hum Immunol. 2007 Mar 12;68(5):309–323. doi: 10.1016/j.humimm.2007.01.019

Figure 7.

Figure 7

Presence of KIR2DS3 in the donor protects against chronic GHVD. Kaplan-Meier analysis and Cox proportional hazard modeling of chronic GVHD in all patients (n=143) transplanted from (i) donors with KIR2DS3 absent (n=63/106) compared to (ii) donors with KIR2DS3 present (n=15/37, p=0.03; hazard ratio=0.5, 95% CI=0.3-0.9).